Table of Contents
HYDERABAD — Aurigene’s parent company, Dr. Reddy’s Laboratories, has recently made a strategic investment in Edity and will provide discovery services in cell therapy to the company.
Edity has developed the first-ever immune cell delivery platform, to enable the selective delivery of intracellular therapeutic proteins to target cells with unprecedented specificity. Edity has multiple product candidates in oncology, gene therapy, autoimmune disorders, and regenerative medicine. To support and accelerate the clinical development of advanced and novel technologies, Edity partnered with Aurigene based on its demonstrated expertise in discovery services for advanced therapies.
Aurigene has a global presence and track record of two decades in supporting global pharmaceutical and biotech companies with accelerated development timelines and cost-effective manufacturing for biologics and small molecules. In biologics, Aurigene has an experienced team of scientists and offers a wide range of discovery and development services for various therapeutic modalities such as antibodies, ADCs, cell therapeutics, and viral vectors.
Akhil Ravi, CEO, Aurigene, said, “We are excited about the collaboration and look forward to working with Edity in building novel technologies. Edity’s cellular reprogramming technology to deliver therapeutic payloads, specifically to target cells, adds a new mechanism to CAR-T based cell therapeutics with the potential to significantly increase the efficacy.”
